Medico Remedies Ltd
Medico Remedies Q2 Results 2026 (FY27) statement: Revenue & Margins
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
- Revenue
- ₹74Cr
- Net profit
- ₹2Cr
- Margin
- 4.3%
Based on Medico Remedies Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Revenue from operations for the quarter ended September 30, 2026: Rs. 7,397.20 lakhs, compared to Rs. 5,263.52 lakhs in Q2 September 2025, reflecting a year-on-year increase of approximately 40.5%. EBITDA for the quarter ended 30 Sep 2026: Rs. 758.04 lakh (Profit before finance costs, depreciation, and tax), up 48.7% YoY from Rs. 509.90 lakh.
From Medico Remedies Ltd's Q2 FY27 earnings-call transcript · updated 9 Nov 2026.
How did Medico Remedies' revenue grow in the September 2026 quarter?
- Revenue from operations for the quarter ended September 30, 2026: Rs. 7,397.20 lakhs, compared to Rs. 5,263.52 lakhs in Q2 September 2025, reflecting a year-on-year increase of approximately 40.5%.
- Sales within India for QE 30.09.2026: Rs. 3,845.90 lakhs, up from Rs. 2,633.62 lakhs in QE 30.06.2026 (quarter-on-quarter comparison).
- Sales outside India for QE 30.09.2026: Rs. 3,532.97 lakhs, decreased from Rs. 4,269.74 lakhs in QE 30.06.2026.
- Total sales (domestic + international) for QE 30.09.2026: Rs. 7,378.87 lakhs versus Rs. 6,903.36 lakhs in QE 30.06.2026.
What happened to Medico Remedies' margins in Q2 FY27?
See what Medico Remedies Ltd said on profitability & margins — free account, 30 seconds.
What capex is Medico Remedies planning?
See what Medico Remedies Ltd said on capital expenditure plans — free account, 30 seconds.
Is Medico Remedies raising money or cutting debt?
See what Medico Remedies Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Medico Remedies' order book?
See what Medico Remedies Ltd said on order book & pipeline — free account, 30 seconds.
Medico Remedies Ltd — Quarterly revenue & net profit
Medico Remedies Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 |
|---|---|
| Revenue | 74 |
| Operating profit (EBITDA) | 3 |
| Operating margin | 4.3% |
| Profit before tax | 3 |
| Net profit (PAT) | 2 |
| EPS (₹) | 0.29 |
Source: Medico Remedies Ltd's results filing to NSE (standalone), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹74 Cr, net profit ₹2 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Medico Remedies Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Medico Remedies Ltd Q2 FY27 results?
Revenue from operations for the quarter ended September 30, 2026: Rs. 7,397.20 lakhs, compared to Rs. 5,263.52 lakhs in Q2 September 2025, reflecting a year-on-year increase of approximately 40.5%. EBITDA for the quarter ended 30 Sep 2026: Rs. 758.04 lakh (Profit before finance costs, depreciation, and tax), up 48.7% YoY from Rs. 509.90 lakh.
What is Medico Remedies Ltd share price analysis?
Medico Remedies Ltd currently shows a neutral. The stock trades at a P/E of 11.3 with a market cap of ₹156 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Medico Remedies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.